These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 20138805)

  • 1. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
    Martin M; Goyette N; Ives J; Boivin G
    J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
    Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
    Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome.
    Martin M; Gilbert C; Covington E; Boivin G
    J Infect Dis; 2006 Sep; 194(5):579-83. PubMed ID: 16897654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
    Boivin G; Goyette N; Gilbert C; Covington E
    J Med Virol; 2005 Nov; 77(3):425-9. PubMed ID: 16173018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
    Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
    J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
    Hantz S; Garnier-Geoffroy F; Mazeron MC; Garrigue I; Merville P; Mengelle C; Rostaing L; Saint Marcoux F; Essig M; Rerolle JP; Cotin S; Germi R; Pillet S; Lebranchu Y; Turlure P; Alain S;
    J Antimicrob Chemother; 2010 Dec; 65(12):2628-40. PubMed ID: 20961907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.
    Iwasenko JM; Scott GM; Rawlinson WD; Keogh A; Mitchell D; Chou S
    J Med Virol; 2009 Mar; 81(3):507-10. PubMed ID: 19152402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
    Boutolleau D; Deback C; Bressollette-Bodin C; Varnous S; Dhedin N; Barrou B; Vernant JP; Gandjbakhch I; Imbert-Marcille BM; Agut H
    Antiviral Res; 2009 Feb; 81(2):174-9. PubMed ID: 19063923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
    Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
    Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient.
    Bachmann R; Hamprecht K; Lange J; Ladurner R; Nadalin S; Jahn G; Königsrainer A; Heininger A
    Infection; 2013 Aug; 41(4):875-9. PubMed ID: 23546999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.
    Sohrabi M; Behzadian F; Hosseini SM; Lashini H
    Arch Iran Med; 2016 Oct; 19(10):700-703. PubMed ID: 27743434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis.
    Boivin G; Goyette N; Farhan M; Ives J; Elston R
    J Clin Virol; 2012 Mar; 53(3):208-13. PubMed ID: 22237003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients.
    Kim YJ; Boeckh M; Cook L; Stempel H; Jerome KR; Boucek R; Burroughs L; Englund JA
    Transpl Infect Dis; 2012 Dec; 14(6):611-7. PubMed ID: 23198963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
    Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
    J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
    Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.
    Gracia-Ahufinger I; Gutiérrez-Aroca J; Cordero E; Vidal E; Cantisán S; del Castillo D; Martín-Gandul C; Rivero A; Torre-Cisneros J
    Transplantation; 2013 Apr; 95(8):1015-20. PubMed ID: 23407543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.